RVNC News and Press, Revance Therapeutics Inc. From 05/10/21

Revance Therapeutics, Inc. (RVNC) Q1 2021 Results Conference Call May 10, 2021 04:30 PM ET Company Participants Jessica Serra - Head, IR and ESG Mark Foley - President and CEO Toby Schilke - CFO Dr. Abhay Joshi - COO and President, R&D and Product Operations Dustin Sjuts - Chief Commercia...

Revance Therapeutics (RVNC): Q1 GAAP EPS of -$1.08 beats by $0.11.Revenue of $13.2M (+21900.0% Y/Y) beats by $2.37M.Press Release For further details see: Revance Therapeutics EPS beats by $0.11, beats on revenue

- Q1 revenue for the RHA® Collection of dermal fillers of $11.6 million - HintMD’s processing volume run-rate more than doubled to over $400 million from the prior quarter - Over 1,500 aesthetic accounts activated across products and services at quarter-end...

Conference Call Scheduled for Monday, May 10, 2021 at 4:30 p.m. ET. Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release first quarter 2021 financial result...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced an upcoming presentation at The American Society for Aesthetic Plastic Surgery (ASAPS) Aesthetic Meeting 2021, being held at The Miami Beach Conv...

Revance Therapeutics (RVNC) announces that collaborator Shanghai Fosun Pharmaceutical has initiated Phase 3 trials of DaxibotulinumtoxinA for Injection in China, for the treatment of glabellar lines and cervical dystonia.Both trials enrolled and dosed their first patients in April.Revance ent...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly-owned subsidiary of Shanghai Fosun Pharm...

-New DaxibotulinumtoxinA for Injection results from the SAKURA Phase 3 program will be presented, as well as two additional ePoster presentations- -Additional ePoster presentation highlighting findings from a study evaluating hyaluronic acid (HA) filler manufacturing technolog...

Revance Therapeutics (RVNC) has inked a commercial supply agreement with Lyophilization Services of New England, a contract development and manufacturing services organization.Per the terms of the arrangement, Lyophilization will become a non-exclusive manufacturer and supplier of t...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the 20th Annual Needham Virtual Healthcare Conference, a fully virtual management access conference, taking ...